Product apis-protein-tyrosine-kinase

Home > products > apis> protein-tyrosine-kinase

Catalog	name	Description	price
R-C-479	Glesatinib(MGCD265) CAS:875337-44-3	MGCD265 is a multitargeted tyrosine kinase inhibitor that binds to and inhibits the phosphorylation of several RTKs,including the c-Met receptor (HGFR);the Tek/Tie-2 receptor;VEGFR types 1,2,and 3;and MST1R.	price>
R-C-484	NVP-BGJ398 cas:872511-34-7	Infigratinib(BGJ-398; NVP-BGJ398) is a potent inhibitor of the FGFR family with IC50s of 0.9 nM,1.4 nM,1 nM,and 60 nM for FGFR1,FGFR2,FGFR3,and FGFR4, respectively.	price>
R-C-485	BAY73-4506(Regorafenib) cas:755037-03-7	Regorafenib (BAY73-4506,Fluoro-Sorafenib,Resihance,Stivarga) is a multi-target inhibitor for VEGFR1,VEGFR2,VEGFR3,PDGFRβ,Kit (c-Kit),RET (c-RET) and Raf-1 with IC50 of 13 nM/4.2 nM/46 nM,22 nM,7nM,1.5 nM and 2.5 nM in cell-free assays,respectively.Regorafenib induces autophag.	price>
R-C-488	Pelitinib(EKB-569) cas:257933-82-7	Pelitinib(EKB-569;WAY-EKB 569)is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM;also slightly inhibits Src,MEK/ERK and ErbB2 with IC50s of 282,800,and 1255 nM,respectively.	price>
R-C-489	Neratinib(HKI-272) cas:698387-09-6	Neratinib(HKI-272)is a highly selective HER2 and EGFR inhibitor with IC50 of 59 nM and 92 nM in cell-free assays;weakly inhibits KDR and Src,no significant inhibition to Akt,CDK1/2/4,IKK-2,MK-2,PDK1,c-Raf and c-Met.	price>
R-C-490	Imatinib cas:152459-95-5	Imatinib (STI571) is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL,v-Abl,PDGFR and c-kit kinase activity.Imatinib (STI571) works by binding close to the ATP binding site,locking it in a closed or self-inhibited conformation,therefore inhibiting the enzyme activity of the protein semicompetitively.Imatinib also is an inhibitor of SARS-CoV and MERS-CoV.	price>
R-C-491	Erlotinib HCL cas:183319-69-9	Erlotinib is an epidermal growth factor receptor inhibitor (EGFR inhibitor). Erlotinib HCl was approved.Erlotinib binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor.For the signal to be transmitted,two EGFR molecules need to come together to form a homodimer.These then use the molecule of ATP to trans-phosphorylate each other on tyrosine residues,which generates phosphotyrosine residues,recruiting the phosphotyrosine-binding proteins to EGFR to assemble protein complexes that transduce signal cascades to the nucleus or activate other cellular biochemical processesWhen erlotinib binds to EGFR,formation of phosphotyrosine residues in EGFR is not possible and the signal cascades are not initiated.	price>
R-C-492	Afatinib(BIBW2992) cas:439081-18-2	BIBW2992(Afatinib)is tyrosine kinase inhibitor(TKI)that irreversibly inhibits human epidermal growth factor receptor 2(Her2)and epidermal growth factor receptor(EGFR) kinases.	price>
R-C-502	Cabozantinib (XL184，BMS-907351) cas:849217-68-1	Cabozantinib (XL184,BMS-907351) is a potent VEGFR2 inhibitor with IC50 of 0.035 nM and also inhibits c-Met,Ret,Kit,Flt-1/3/4,Tie2,and AXL with IC50 of 1.3 nM,4 nM,4.6 nM,12 nM/11.3 nM/6 nM,14.3 nM and 7 nM in cell-free assays, respectively.Cabozantinib induces PUMA-dependent apoptosis in colon cancer cells via AKT/GSK-3β/NF-κB signaling pathway.	price>
R-C-505	Canetinib cas:267243-28-7	Canertinib(CI-1033,PD183805)is a pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 1.5 nM and 9.0 nM,no activity to PDGFR, FGFR,InsR,PKC,or CDK1/2/4.	price>

...